Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine

Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine NEW YORK and AMSTERDAM, January 26, 2021 – Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company’s […]

Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies

Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies SOUTH SAN FRANCISCO, Calif.  and AMSTERDAM, The Netherlands – October 13, 2020 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and […]

Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors

Four Additional Board Members Appointed to Complement Founding Expertise NEW YORK and AMSTERDAM, October 6, 2020 – Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Franz B. Humer, Ph.D., as Executive Chairman of the Board of […]

Franz B. Humer, Ph.D.

A world-renowned pharmaceutical industry trailblazer, Dr. Humer served as Chairman and Chief Executive Officer of Roche Holding, Ltd. over a period of 16 years before retiring in 2014. Dr. Humer joined Roche in 1995 as Head of the Pharmaceuticals Division and Member of the Board. He was appointed CEO in 1998 and Chairman of the […]

Ton N.M. Schumacher, Ph.D.

Ton N.M. Schumacher, Ph.D., is a Co-Founder of Neogene and Principal Investigator at The Netherlands Cancer Institute, Oncode Institute member, and Professor of Immunotechnology at Leiden University Medical Center. Dr. Schumacher previously co-founded AIMM Therapeutics, Neon Therapeutics and T Cell Factory and served as Chief Scientific Officer of Kite Pharma EU. In addition, Dr. Schumacher […]

Gavin M. Bendle, Ph.D.

Dr. Gavin M. Bendle is the Vice President of Research and Development at Neogene Therapeutics. He has been actively engaged in the field of adoptive T cell therapy of cancer for over 17 years and has co-authored numerous publications on this subject. Before joining Neogene, Dr. Bendle was a Senior Director of Cell Therapy at […]

Sean Algeo, CPA

Sean Algeo is the Treasurer and Corporate Controller of Neogene Therapeutics. He also serves as Vice President-Finance at Two River Consulting, LLC, where he is responsible for all financial and accounting activities of Two River and certain of its portfolio companies. Prior to joining Two River in 2018, Mr. Algeo was a Senior Manager at […]

Christopher Wilfong, M.B.A.

Christopher Wilfong is the Chief Business Officer at Neogene Therapeutics. In addition, Mr. Wilfong is an Operating Partner at Two River Consulting, LLC, where he is a co-founder and has held interim management positions in several Two River portfolio companies, including Kite Pharma, Inc., Kronos Bio, Inc., Arno Therapeutics, Inc., and Nile Therapeutics, Inc. Prior […]

David M. Tanen

David M. Tanen is Corporate Secretary of Neogene and a Partner and Co-Founder of Two River Consulting, which specializes in creating, operating and financing development-stage life science companies. Mr. Tanen is also a Co-Founder of Kite Pharma, where he served as an officer and General Counsel from its inception until its acquisition by Gilead Sciences; […]